Recent Finacing
Recent Raise
WindMIL Therapeutics develops marrow-infiltrating lymphocyte (MIL) therapies by extracting, activating, and expanding bone marrow–derived memory T cells for multiple myeloma and solid tumor trials and engineered CAR-T applications.
